246 related articles for article (PubMed ID: 29654026)
1. Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study.
Vallejo-Torres L; Pujol M; Shaw E; Wiegand I; Vigo JM; Stoddart M; Grier S; Gibbs J; Vank C; Cuperus N; van den Heuvel L; Eliakim-Raz N; Carratala J; Vuong C; MacGowan A; Babich T; Leibovici L; Addy I; Morris S;
BMJ Open; 2018 Apr; 8(4):e020251. PubMed ID: 29654026
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of hospitalised patients with catheter-associated urinary tract infection in countries with a high rate of multidrug-resistance: the COMBACTE-MAGNET RESCUING study.
Gomila A; Carratalà J; Eliakim-Raz N; Shaw E; Tebé C; Wolkewitz M; Wiegand I; Grier S; Vank C; Cuperus N; Van den Heuvel L; Vuong C; MacGowan A; Leibovici L; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2019; 8():198. PubMed ID: 31827779
[TBL] [Abstract][Full Text] [Related]
3. Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING).
Shaw E; Addy I; Stoddart M; Vank C; Grier S; Wiegand I; Leibovici L; Eliakim-Raz N; Vallejo-Torres L; Morris S; MacGowan A; Carratalà J; Pujol M;
BMJ Open; 2016 Jul; 6(7):e011500. PubMed ID: 27473949
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
[TBL] [Abstract][Full Text] [Related]
5. The excess financial burden of multidrug resistance in severe gram-negative infections in Singaporean hospitals.
Ng E; Earnest A; Lye DC; Ling ML; Ding Y; Hsu LY
Ann Acad Med Singap; 2012 May; 41(5):189-93. PubMed ID: 22760715
[TBL] [Abstract][Full Text] [Related]
6. Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections.
Tabak YP; Sung AH; Ye G; Vankeepuram L; Gupta V; McCann E
J Hosp Infect; 2019 May; 102(1):37-44. PubMed ID: 30503367
[TBL] [Abstract][Full Text] [Related]
7. Direct medical costs of urinary tract infections by Gram-negative bacilli resistant to beta-lactams in a tertiary care hospital in Medellín, Colombia.
Vargas-Alzate CA; Higuita-Gutiérrez LF; Jiménez-Quiceno JN
Biomedica; 2019 May; 39(s1):35-49. PubMed ID: 31529847
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Healthcare Utilization Related to Multidrug-Resistant Gram-Negative Infections in Community Hospitals.
Dicks KV; Anderson DJ; Baker AW; Sexton DJ; Lewis SS
Infect Control Hosp Epidemiol; 2017 Jan; 38(1):31-38. PubMed ID: 27724988
[TBL] [Abstract][Full Text] [Related]
9. Healthcare-Associated Infections Due to Multidrug-Resistant Organisms: a Surveillance Study on Extra Hospital Stay and Direct Costs.
Giraldi G; Montesano M; Napoli C; Frati P; La Russa R; Santurro A; Scopetti M; Orsi GB
Curr Pharm Biotechnol; 2019; 20(8):643-652. PubMed ID: 30961489
[TBL] [Abstract][Full Text] [Related]
10. In-hospital costs of community-acquired colonization with multidrug-resistant organisms at a German teaching hospital.
Engler-Hüsch S; Heister T; Mutters NT; Wolff J; Kaier K
BMC Health Serv Res; 2018 Sep; 18(1):737. PubMed ID: 30257671
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: impact of antimicrobial resistance in a large hospitalised cohort.
Shaw E; Benito N; Rodríguez-Baño J; Padilla B; Pintado V; Calbo E; Pallarés MA; Gozalo M; Ruiz-Garbajosa P; Horcajada JP;
J Infect; 2015 Mar; 70(3):247-54. PubMed ID: 25305497
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections.
Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A
BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524
[TBL] [Abstract][Full Text] [Related]
13. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
[TBL] [Abstract][Full Text] [Related]
14. Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia.
Shields RK; Zhou Y; Kanakamedala H; Cai B
BMC Infect Dis; 2021 Jun; 21(1):572. PubMed ID: 34126951
[TBL] [Abstract][Full Text] [Related]
15. Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.
Chen GJ; Pan SC; Foo J; Morel C; Chen WT; Wang JT
J Microbiol Immunol Infect; 2019 Oct; 52(5):807-815. PubMed ID: 31029529
[TBL] [Abstract][Full Text] [Related]
16. Clinical management of cUTI, cIAI, and HABP/VABP attributable to carbapenem-resistant Gram-negative infections in Spain.
Ferrer R; Fariñas MC; Maseda E; Salavert M; Bou G; Díaz-Regañón J; López D; Lozano V; Gómez-Ulloa D; Fenoll R; Lara N; McCann E
Rev Esp Quimioter; 2021 Dec; 34(6):639-650. PubMed ID: 34806858
[TBL] [Abstract][Full Text] [Related]
17. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series.
Pastewski AA; Caruso P; Parris AR; Dizon R; Kopec R; Sharma S; Mayer S; Ghitan M; Chapnick EK
Ann Pharmacother; 2008 Sep; 42(9):1177-87. PubMed ID: 18664609
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections.
Kongnakorn T; Wagenlehner F; Falcone M; Tichy E; Di Virgilio R; Baillon-Plot N; Charbonneau C
Int J Antimicrob Agents; 2019 Nov; 54(5):633-641. PubMed ID: 31202921
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and prognosis of complicated urinary tract infections caused by
Gomila A; Carratalà J; Eliakim-Raz N; Shaw E; Wiegand I; Vallejo-Torres L; Gorostiza A; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Vuong C; MacGowan A; Leibovici L; Addy I; Pujol M;
Infect Drug Resist; 2018; 11():2571-2581. PubMed ID: 30588040
[TBL] [Abstract][Full Text] [Related]
20. The impact of initial antibiotic treatment failure: Real-world insights in patients with complicated urinary tract infection.
Karve S; Ryan K; Peeters P; Baelen E; Rojas-Farreras S; Potter D; Rodríguez-Baño J
J Infect; 2018 Feb; 76(2):121-131. PubMed ID: 29128389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
